AliveGen Announces Successful Completion of Phase 1b Multiple-Ascending Dose Clinical Trial for ALG-801
Published
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company dedicated to developing first-in-class and best-in-class therapeutics for treating muscle wasting, metabolic disorders, and neuromuscular diseases, is delighted to announce the successful completion of its Phase 1b multiple-ascending dose (MAD) clinical trial for ALG-801. ALG-801 is a novel, next-generation ligand trap, which selectively sequesters a subset of TGF-beta family, includ
Full Article